WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-33137 | 14-1902018 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
2273 Research Boulevard, Suite 400, Rockville, Maryland | 20850 |
(Address of Principal Executive Offices) | (Zip Code) |
Item 8.01 Other Events.
On August 19, 2014, Emergent BioSolutions Inc. issued a press release announcing that it has entered into an agreement with MorphoSys AG for the joint development and commercialization of ES414, a bi-specific antibody targeting prostate cancer developed by Emergent using its proprietary ADAPTIRTM platform.
A copy of the press release is attached as Exhibit 99 to this Current Report on Form 8−K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99 Press Release issued by Emergent BioSolutions Inc. on August 19, 2014.
Date: August 19, 2014 | EMERGENT BIOSOLUTIONS INC. | |
By: | /s/ A.B. Cruz A.B. Cruz III Executive Vice President & General Counsel |